AstraZeneca supports the growth of the C3i Lymphoma Registry, a project lead by Dr. Isabelle Fleury at Hôpital Maisonneuve-Rosemont
Montreal, December 16, 2021 — The C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the… Read More »
MONTRÉAL QC, November 4, 2021 – C3i Center Inc. has strengthened our position as Canada’s leading one-stop contract development and manufacturing organization operating in the… Read More »
C3i Center Inc. Supports the Manufacturing of the First Canadian-Made CAR-T Cell Therapy for the Treatment of Solid Tumours
An innovative treatment for advanced metastatic HER2-positive tumours has been administered to the first patient in a phase I/II clinical trial. The investigational T-cell antigen… Read More »
C3i Center Inc (Formerly known Centre for Commercialisation of Cancer Immunotherapy) is proud to announce three new additions to its executive team. Louisa Petropoulos has… Read More »
Behind every triumphant headline announcing a new breakthrough medicine, there’s an often untold story of years or even decades of basic research in the lab,… Read More »
Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine and the Ontario Institute for Regenerative Medicine Partner to Boost Stem Cell Commercialization Efforts
Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine (OIRM) and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine (C3i).
Gilead Sciences Canada supports the development of the lymphoma registry at Hôpital Maisonneuve-Rosemont of the CIUSSS-EMTL
The Center for Commercialization of Cancer Immunotherapy (C3i) and the Centre intégré universitaire de santé et de services sociaux de l’Est-de-l’Île-de-Montréal (CIUSSS-EMTL) are proud to announce the participation of Gilead Sciences Canada, Inc. in supporting the development of a Lymphoma Registry.
Triumvira Immunologics Announces Strategic Relationship for GMP Manufacturing with Centre for Commercialisation of Cancer Immunotherapy
Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.
The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce a partnership with Hôpital Maisonneuve-Rosemont (HMR) and Dr. Isabelle Fleury, Hematologist and Medical Oncologist at HMR, to support the development of a Lymphoma Registry.
C3i will attend the Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam from December 5th to 7th to engage with researchers, clinicians and industry leaders in… Read More »
The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce the availability of T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit.
The 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.
Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i
$29 million investment in two commercialization centres will accelerate Canadians’ access to innovative cancer immunotherapies and natural products